Skip to main content
. 2009 Jul 8;106(29):12195–12200. doi: 10.1073/pnas.0900130106

Fig. 4.

Fig. 4.

Agonist action on the localization, maturation and stability of V2R mutants. (A) Localization. Confluent MDCK WT-V2R or V2R-L44P cells were left untreated or treated with 100 nM of the peptide agonist dDAVP, 1 μM the nonpeptide agonists VA88, or the nonpeptide antagonist SR1 for 16 h followed by CLSM analysis. (B) V2R Maturation and stability. MDCK WT-V2R, V2R-L44P, -Y128S, or -P322S cells were left untreated, treated with the nonpeptide agonists VA88, VA89 or OPC51, or treated with the nonpeptide antagonist SR1 for 16 h. Subsequently, receptor proteins were analyzed by immunoblotting. (C) Stability. MDCK WT-V2R, V2R-L44P, -Y128S or -P322S cells were left untreated, treated with 50 μM cycloheximide alone, or supplemented with 1 μM VA88, VA89 or OCP51 for 6 h. Subsequently, receptor proteins were analyzed by immunoblotting.